Who makes hypobaric levobupivacaine with fentanyl?

hypobaric levobupivacaine with fentanyl is developed by USP Hospital La Colina.

What development phase is hypobaric levobupivacaine with fentanyl in?

hypobaric levobupivacaine with fentanyl is FDA-approved (marketed).

Last reviewed 2026-05-14 · How we verify

hypobaric levobupivacaine with fentanyl

USP Hospital La Colina · FDA-approved active Small molecule Quality 0/100

Hypobaric levobupivacaine with fentanyl, marketed by USP Hospital La Colina, is a currently available anesthetic agent. The key composition patent expires in 2028, providing a clear period of exclusivity. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market valuation.

At a glance

Generic name	hypobaric levobupivacaine with fentanyl
Also known as	Chirocane
Sponsor	USP Hospital La Colina
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Selective Unilateral Spinal Anesthesia Versus Selective Sensory Spinal Anesthesia for Knee Arthroscopy Surgery (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

hypobaric levobupivacaine with fentanyl CI brief — competitive landscape report
hypobaric levobupivacaine with fentanyl updates RSS · CI watch RSS
USP Hospital La Colina portfolio CI